Table 1 Patient characteristics

From: Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)

Variables

mFOLFOX6+BEV

mFOLFOX6+CET

P

Age (years)

Median (range)

64 (32.0ā€“80.0)

65 (42.0ā€“79.0)

0.328

Sex

Male

34 (59.6%)

34 (57.6%)

0.825

Ā 

Female

23 (40.4%)

25 (42.4%)

Ā 

ECOG PS

0

51 (89.5%)

51 (86.4%)

0.616

Ā 

1

6 (10.5%)

8 (13.6%)

Ā 

Adjuvant chemotherapy

Yes

3 (5.3%)

2 (3.4%)

0.619

Prior oxaliplatin

Yes

1 (1.8%)

2 (3.4%)

0.579

Location of tumour

Right

9 (15.8%)

14 (23.7%)

0.284

Ā 

Left

48 (84.2%)

45 (76.3%)

Ā 

Tumour status

Synchro/primary tumour

13 (22.8%)

15 (25.4%)

0.771

Ā 

Synchro/no primary tumoura

39 (68.4%)

39 (66.1%)

Ā 
Ā 

Metachronous

5 (8.8%)

5 (8.5%)

Ā 

Number of liver metastases

<5

15 (26.3%)

18 (30.5%)

0.617

Ā 

ā‰„5

42 (73.7%)

41 (69.5%)

Ā 

Diameter of liver metastases

ā‰¤5ā€‰cm

20 (35.1%)

19 (32.2%)

0.742

Ā 

>5ā€‰cm

37 (64.9%)

40 (67.8%)

Ā 
  1. mFOLFOX6 5-fluorouracil/folinic acid, oxaliplatin, BEV bevacizumab, CET cetuximab, ECOG PS Eastern Cooperative Oncology Group performance status
  2. aSynchro/no primary tumour: metastatic tumour diagnosed within 6 months after resection of primary tumour
Back to article page